NEW YORK, NY – [Date of Article Publication] – In a landmark decision poised to redefine personal mobility, Wandercraft, a pioneering French robotics company, has announced that its innovative self-balancing exoskeleton, Eve, has received clearance from the U.S. Food and Drug Administration (FDA). This monumental approval paves the way for eligible wheelchair users to experience hands-free upright mobility beyond the confines of rehabilitation centers, integrating standing and walking into the fabric of their daily lives.
The FDA clearance for Eve represents a significant leap forward in assistive technology, offering a new frontier of independence for individuals with spinal cord injuries. Unlike previous exoskeletons primarily designed for clinical rehabilitation, Eve is engineered for personal use in everyday environments, promising to transform routine activities into moments of profound empowerment.
A New Dawn for Upright Mobility
Wandercraft’s Eve is designed to complement, not replace, the wheelchair, offering eligible adults with spinal cord injuries (at any level) the ability to stand, walk, bend, turn, and utilize their hands freely. This is made possible by its advanced self-balancing technology, which allows users to operate the device with a remote control while maintaining stability without the need for crutches or other external support.
For countless individuals, opportunities to stand and move upright have historically been confined to structured rehabilitation sessions. Eve shatters these limitations, bringing the profound benefits of verticality – from improved physical health and psychological well-being to enhanced social interaction – directly into homes and immediate outdoor spaces like patios and terraces. The device is intended for use on level indoor surfaces and adjacent open-air areas, under the supervision of a specially trained companion, ensuring safety and optimal utilization.
This clearance is a testament to Wandercraft’s relentless pursuit of innovation, building upon the foundational success of its rehabilitation exoskeleton, Atalante X. Atalante X is currently utilized in over 150 rehabilitation and research centers worldwide, providing a robust clinical heritage that underpins Eve’s development. The transition from a clinical rehabilitation tool to a personal mobility device marks a pivotal moment in the evolution of healthcare robotics.
The Journey to Personal Empowerment: A Chronology of Innovation
Wandercraft’s vision for personal upright mobility has been a journey spanning years of dedicated research, development, and rigorous testing. The company, founded with the ambitious goal of making walking accessible to all, has systematically built its expertise in dynamic balance and bipedal robotics.
Early Foundations with Atalante X: The genesis of Eve lies in the extensive experience gained from Atalante X. This earlier model, a highly sophisticated self-balancing rehabilitation exoskeleton, has been instrumental in clinical settings, helping patients relearn walking patterns and regain strength. The real-world data and insights gathered from Atalante X’s deployment in numerous global facilities provided invaluable lessons in user interface design, safety protocols, and the intricacies of human-robot interaction in medical contexts. This strong clinical pedigree allowed Wandercraft to refine its core technology and apply it to a more personal, less supervised setting.
Rigorous Clinical Trials for Eve: The path to FDA clearance for Eve involved comprehensive, multi-site clinical trials. These trials, critical for demonstrating the device’s safety, efficacy, and usability in everyday scenarios, were conducted at leading institutions. Key sites included the James J. Peters Department of Veterans Affairs Medical Center in the Bronx, NY; Kessler Foundation in West Orange, NJ; and Walk in New York in New York City, NY. Participants, representing a diverse range of spinal cord injury severities, underwent structured training, followed by functional, usability, and task-based assessments designed to mirror real-world activities. This extensive evaluation process ensured that Eve was not only technically proficient but also practically viable for personal use.
From Rehabilitation to Home: The Seamless Transition: Matthieu Masselin, co-founder and CEO of Wandercraft, articulated the profound significance of this progression: "FDA clearance of Eve marks one of the most important moments in Wandercraft’s history and a significant step for the people, families, clinicians, researchers, and partners who helped make it possible. Together, Atalante X and Eve may offer eligible users a pathway from walking during rehabilitation to upright mobility at home, whether making coffee at the kitchen counter, reaching for a book, or spending time with friends on the patio." This statement underscores the strategic continuity between Wandercraft’s offerings, creating a holistic care pathway for individuals seeking to reclaim upright mobility.
Commercial Launch and Accessibility Preparations: With FDA clearance secured, Wandercraft is now meticulously preparing for Eve’s commercial launch in the United States, slated for September 17, 2026. This launch will be marked by an exclusive unveiling event at the Cure healthcare innovation campus in New York City, presented in collaboration with the United Spinal Association, which is celebrating its 80th anniversary. This livestreamed program aims to unite individuals living with spinal cord injuries, caregivers, clinicians, researchers, policymakers, and Eve pilots, symbolizing the crucial transition of self-balancing exoskeleton technology from clinical rehabilitation to widespread personal application. The company has also established a robust framework for access, including specialized training, reimbursement assistance, and a network of distribution partners, ensuring that the technology reaches those who need it most.
Supporting Data: The Science Behind the Stride
Eve’s FDA clearance is built upon a strong foundation of scientific evidence and technological prowess, promising tangible benefits across physical, psychological, and social dimensions for its users.
Technical Ingenuity: Self-Balancing and Hands-Free Operation: At the heart of Eve’s innovation is its sophisticated self-balancing technology. This proprietary system employs advanced sensors and algorithms to continuously monitor and adjust the user’s center of gravity, maintaining stability dynamically. This capability liberates users from relying on crutches or walkers, allowing for genuine hands-free operation. This freedom is critical for performing activities of daily living (ADLs) such as cooking, cleaning, reaching for objects, and engaging in hobbies. The remote control interface is designed for intuitive operation, putting the user in control of their movement.
Clinical Validation and User-Reported Outcomes: The three-site clinical trial provided compelling evidence for Eve’s readiness for personal use. The trial focused on critical aspects including safety, functional performance, and usability in environments reflecting everyday life. Participants successfully learned to operate Eve and complete tasks relevant to personal use, demonstrating proficiency in walking on level surfaces, navigating tight spaces, and performing various ADLs.
Crucially, the study went beyond mere technical performance, incorporating user-reported outcomes that illuminated the device’s profound impact. Gail Forrest, PhD, director of the Tim and Caroline Reynolds Center for Spinal Stimulation at Kessler Foundation, emphasized this aspect: "What makes these findings meaningful is that the technology was evaluated not only on engineering performance but also on how users and companions could safely integrate it into real-world activities. The combination of functional performance, usability, and user-reported outcomes gives this technology substantial clinical relevance."
Participants reported significant improvements in several aspects of their daily lives:
- Physical Health: Enhanced endurance during daily activities, reduction in lower-limb spasticity, improved sitting balance, and even reported improvements in sleep quality and bladder/bowel function.
- Psychological Well-being: A marked increase in confidence and a sense of empowerment. Caroline Laubach, a Wandercraft Test Pilot, shared her transformative experience: "For years, I experienced much of the world while seated. Using Eve transformed ordinary moments in ways I never expected, like having conversations eye-to-eye whether seated or standing, getting a cup from the highest kitchen cabinet, and simply bringing a new type of confidence into my life."
- Social Interaction: The ability to engage in conversations at eye level and participate more fully in social gatherings, fostering a greater sense of inclusion and connection.
These findings are particularly impactful given the prevalence of paralysis. According to the Christopher & Dana Reeve Foundation, over five million people in the United States live with paralysis, including hundreds of thousands with spinal cord injuries. For many, the ability to stand and move upright carries deep personal meaning, impacting not only physical health but also social interactions and overall participation in life.
Reimbursement and Accessibility Framework: Understanding that groundbreaking technology is only as valuable as its accessibility, Wandercraft has made substantial investments in establishing a robust reimbursement and access pathway.
- Medicare Coverage: Medicare has provided a reimbursement pathway for eligible personal exoskeleton users since 2024, under its Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) program, using billing code K1007. Wandercraft anticipates Eve could become eligible for Medicare reimbursement within 60 to 90 days of its commercial launch.
- Dedicated Access Specialists: The company has established a specialized team to assist users and their care teams in navigating complex claim submissions, understanding coverage requirements, addressing reimbursement questions, and exploring available financing options.
- Broadening Access: Plans are underway to broaden patient access through private payers and other funding sources, ensuring that qualified users can bring Eve home.
Comprehensive Training and Support: Prior to use, individuals will undergo a rigorous "care pathway" that includes a clinical assessment, an individualized device fitting, and comprehensive training. This training, typically comprising five two-hour sessions completable in as little as one week, covers essential skills such as transfers, remote-controller operation, walking on level surfaces, navigating tight spaces, performing ADLs, and crucial safety and emergency procedures. A specially trained companion is also required to complete this training alongside the user.
Official Responses: Voices of Hope and Progress
The FDA clearance for Eve has elicited strong positive reactions from Wandercraft’s leadership, test pilots, and clinical partners, all highlighting the profound implications for the disability community.
Matthieu Masselin, Wandercraft CEO: "FDA clearance of Eve marks one of the most important moments in Wandercraft’s history and a significant step for the people, families, clinicians, researchers, and partners who helped make it possible. Together, Atalante X and Eve may offer eligible users a pathway from walking during rehabilitation to upright mobility at home, whether making coffee at the kitchen counter, reaching for a book, or spending time with friends on the patio." Masselin’s statement not only celebrates the achievement but also paints a vivid picture of the everyday impact Eve is poised to deliver, emphasizing the continuum of care from clinic to home.
Caroline Laubach, Wandercraft Test Pilot: Laubach’s personal testimony is a powerful illustration of Eve’s transformative potential. "For years, I experienced much of the world while seated. Using Eve transformed ordinary moments in ways I never expected, like having conversations eye-to-eye whether seated or standing, getting a cup from the highest kitchen cabinet, and simply bringing a new type of confidence into my life." Her words resonate with the aspirations of many wheelchair users, underscoring the device’s ability to restore not just physical function but also a sense of self-esteem and social parity.
Dr. Gail Forrest, Kessler Foundation: Dr. Forrest’s expert opinion validates the scientific rigor behind Eve’s development and clinical evaluation. "What makes these findings meaningful is that the technology was evaluated not only on engineering performance but also on how users and companions could safely integrate it into real-world activities. The combination of functional performance, usability, and user-reported outcomes gives this technology substantial clinical relevance." Her emphasis on "real-world activities" and "user-reported outcomes" highlights the holistic approach taken in assessing Eve’s true value, moving beyond mere technical specifications to embrace the human experience.
Partnerships for Broadened Access: The extensive network of partnerships Wandercraft has cultivated underscores a collective commitment to making Eve widely available.
- Walk US: As a key partner specializing in neurorehabilitation using Atalante X, Walk US will serve as a crucial hub for Eve evaluations, training, demonstrations, and community education, with its flagship New York location and a second planned in Miami.
- National Seating & Mobility (NSM): Serving as Wandercraft’s exclusive Complex Rehabilitation Technology (CRT) distribution partner for Eve, NSM’s vast network of over 180 locations across the U.S. and Canada will be instrumental in supporting evaluation, access, delivery, and service. This partnership is vital for ensuring seamless integration into existing healthcare infrastructure.
- Good Shepherd Rehabilitation: As the exclusive Eve partner in Pennsylvania’s Lehigh Valley, Good Shepherd’s Hyland Center will provide an access point for eligible users and their companions to learn about and experience the technology firsthand.
- USVetServ: This Service-Disabled Veteran-Owned Small Business will act as an authorized independent distributor for the U.S. Department of Veterans Affairs (VA), ensuring that veterans, who often face unique mobility challenges, have access to Eve and Atalante X through VA Medical Centers and facilities nationwide. This commitment reflects Wandercraft’s dedication to supporting those who have served.
These collaborations collectively form the backbone of the clinical, reimbursement, distribution, training, and service infrastructure necessary to translate FDA clearance into tangible, meaningful access for eligible individuals.
Implications: Reshaping the Future of Mobility and Independence
The FDA clearance of Wandercraft’s Eve is more than just a regulatory milestone; it is a catalyst for profound implications across healthcare, technology, and society, signaling a new era for personal mobility.
Transforming the Landscape of Assistive Technology: Eve represents a paradigm shift in how assistive technologies are conceived and utilized. By enabling hands-free, self-balancing upright mobility in personal environments, it moves beyond traditional rehabilitation models, which often limit upright activity to supervised clinical settings. This evolution empowers individuals to integrate standing and walking into their daily routines, fostering a greater sense of autonomy and independence. It sets a new benchmark for what is possible with wearable robotics.
Enhanced Quality of Life and Health Outcomes: The benefits of upright mobility extend far beyond just walking. Standing and walking can significantly improve circulation, bone density, muscle tone, and respiratory function. The reported improvements in bladder and bowel function, lower-limb spasticity, and sitting balance highlight Eve’s potential to contribute to overall physiological health, reducing secondary complications often associated with prolonged sitting. Psychologically, the ability to interact with the world from a standing perspective can dramatically boost self-confidence, reduce feelings of isolation, and enhance mental well-being.
The Evolution of Healthcare Robotics: Eve’s success demonstrates the increasing sophistication and practical application of advanced robotics and artificial intelligence in healthcare. The ability to achieve dynamic, self-balancing motion in a personal device underscores significant advancements in control systems, sensor technology, and battery efficiency. This clearance will likely spur further innovation in the field, encouraging other developers to pursue personal-use medical exoskeletons that address a wider range of mobility impairments.
Economic and Social Impact: The widespread availability of Eve could have significant economic and social ripple effects. For individuals, greater independence can lead to increased participation in work, education, and community activities. For healthcare systems, improved health outcomes and reduced secondary complications may lead to lower long-term care costs. Socially, the normalization of personal exoskeletons could foster greater inclusivity and challenge existing perceptions of disability, promoting environments where upright mobility is more readily accommodated.
Challenges and the Path Forward: While the future looks promising, challenges remain. Broadening insurance coverage beyond Medicare to include private payers is crucial for widespread access. Continued research into long-term effects, user adaptations, and potential improvements will also be essential. Furthermore, ensuring equitable access globally will require navigating diverse regulatory and healthcare systems.
Wandercraft’s commitment to access, exemplified by its dedicated support team and strategic partnerships, indicates a holistic approach to bringing this technology to life. The upcoming commercial launch in September 2026 and the exclusive unveiling event with the United Spinal Association will be critical moments in realizing this vision.
For those eager to learn more or register to watch the livestream of the official unveiling on September 17, 2026, at 6 p.m. ET, visit: https://share.hsforms.com/2iWRkru7sTcmpTGdO6_Lo1Q5aapy. Individuals interested in being considered for an early experience with Eve before its widespread availability can complete an online inquiry form at: https://www.wandercraft.eu/form.
The FDA clearance of Eve marks not just an advancement in medical technology, but a significant step towards a future where greater independence and dignity through personal mobility become a reality for many more individuals living with spinal cord injuries.
Learn more at: Wandercraft.eu.
